Aktienanalyse zu Enlivex Ltd (ENLV)ENLVEnlivex Ltd

Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Enlivex Therapeutics is not a good buy right now due to its current price of $1.28, which is significantly below the analyst target of $80, but the stock has seen a staggering 99.29% decline year-to-date, indicating extreme volatility and risk. The RSI is at an extremely low level of 8.773, suggesting the stock is oversold, but this could also indicate persistent weakness. The main risk is the upcoming earnings report on November 13, 2026, where the EPS estimate is -4.48, which may lead to further declines if results disappoint.